AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

UK Assets Acquired

UK Assets Acquired % Chg.

UK Assets Acquired Common Size

Rest of Europe Assets Acquired

Rest of Europe Assets Acquired % Chg.

Rest of Europe Assets Acquired Common Size

The Americas Assets Acquired

The Americas Assets Acquired % Chg.

The Americas Assets Acquired Common Size

Asia, Africa & Australasia Assets Acquired

Asia, Africa & Australasia Assets Acquired % Chg.

Asia, Africa & Australasia Assets Acquired Common Size

Other Capital Expenditures by Geography

Other Capital Expenditures by Geography % Chg.

Other Capital Expenditures by Geography Common Size

Total Capital Expenditures by Geography

Total Capital Expenditures by Geography Common Size

Total Capital Expenditures by Geography % Chg.

Capital Expenditures by Geography

UK Operating Profit

UK Operating Profit % Chg.

UK Operating Profit Common Size

Rest of Europe Operating Profit

Rest of Europe Operating Profit % Chg.

Rest of Europe Operating Profit Common Size

The Americas Operating Profit

The Americas Operating Profit % Chg.

The Americas Operating Profit Common Size

Asia, Africa & Australasia Operating Profit

Asia, Africa & Australasia Operating Profit % Chg.

Asia, Africa & Australasia Operating Profit Common Size

Total EBIT by Geography

Total EBIT by Geography Common Size

Total EBIT by Geography % Chg.

EBIT by Geography

UK Revenue

UK Revenue % Chg.

UK Revenue Common Size

Rest of Europe Revenue

Rest of Europe Revenue % Chg.

Rest of Europe Revenue Common Size

The Americas Revenue

The Americas Revenue % Chg.

The Americas Revenue Common Size

Asia, Africa & Australasia Revenue

Asia, Africa & Australasia Revenue % Chg.

Asia, Africa & Australasia Revenue Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Oncology Revenue

Oncology Revenue % Chg.

Oncology Revenue Common Size

BioPharmaceuticals: CVRM Revenue

BioPharmaceuticals: CVRM Revenue % Chg.

BioPharmaceuticals: CVRM Revenue Common Size

BioPharmaceuticals: R&I Revenue

BioPharmaceuticals: R&I Revenue % Chg.

BioPharmaceuticals: R&I Revenue Common Size

BioPharmaceuticals V&I Revenue

BioPharmaceuticals V&I Revenue % Chg.

BioPharmaceuticals V&I Revenue Common Size

Rare Disease Revenue

Rare Disease Revenue % Chg.

Rare Disease Revenue Common Size

Other Medicines Revenue

Other Medicines Revenue % Chg.

Other Medicines Revenue Common Size

COVID-19 Revenue

COVID-19 Revenue % Chg.

COVID-19 Revenue Common Size

Collaboration Revenue

Collaboration Revenue % Chg.

Collaboration Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	Sep '25	Jun '25
Oncology Revenue	6,636	6,312
BioPharmaceuticals: CVRM Revenue	3,216	3,264
BioPharmaceuticals: R&I Revenue	2,259	2,150
BioPharmaceuticals V&I Revenue	416	185
Rare Disease Revenue	2,416	2,294
Other Medicines Revenue	237	244
COVID-19 Revenue	—	—
Collaboration Revenue	11	8
Other Revenue	—	—
Total Revenue	15,191	14,457